Vaccinex’s VX15 Antibody for Huntington’s Fast Tracked by FDA
Vaccinex‘s VX15, a novel clinical stage monoclonal antibody for Huntington’s disease (HD) treatment, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). VX15 blocks the activity of semaphorin 4D (SEMA4D), a molecule that is thought to promote chronic inflammatory responses in the brain. “We are very pleased…